Cargando…
Impact of ALK variants on brain metastasis and treatment response in advanced NSCLC patients with oncogenic ALK fusion
BACKGROUND: To investigate the impact of ALK variants on the features of brain metastases (BM), the outcome of chemotherapy and targeted therapy using crizotinib, as well as the progression pattern in patients with ALK fusion. METHODS: Patients with ALK fusion were retrospectively collected from Jan...
Autores principales: | Qiao, Meng, Zhao, Chao, Liu, Qian, Wang, Yan, Shi, Jingyun, Ng, Terry L., Zhou, Fei, Li, Xuefei, Jiang, Tao, Yang, Shuo, Gao, Guanghui, Xiong, Anwen, Li, Jiayu, Li, Wei, Wu, Fengying, Chen, Xiaoxia, Su, Chunxia, Ren, Shengxiang, Zhou, Caicun, Zhang, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481619/ https://www.ncbi.nlm.nih.gov/pubmed/32953517 http://dx.doi.org/10.21037/tlcr-19-346 |
Ejemplares similares
-
Detecting ALK, ROS1 and RET Fusion Genes in Cell Block Samples()()
por: Zhao, Chao, et al.
Publicado: (2014) -
Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF
por: Zhuang, Xibin, et al.
Publicado: (2019) -
ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019) -
ALK and NSCLC: Targeted therapy with ALK inhibitors
por: Hallberg, Bengt, et al.
Publicado: (2011) -
Metastatic EML4-ALK fusion detected by circulating DNA genotyping in an EGFR-mutated NSCLC patient and successful management by adding ALK inhibitors: a case report
por: Liang, Wenhua, et al.
Publicado: (2016)